US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the 3D Printed Drugs market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the 3D Printed Drugs market." 3D Printed Drugs Market are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The global 3D Printed Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on 3D Printed Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall 3D Printed Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Aprecia Pharmaceuticals GlaxoSmithKline Plc Hewlett Packard Caribe BV LLC 3D Printer Drug Machine FabRx Ltd ... Segment by Regions North America Europe China Japan Segment by Type Spritam Others Segment by Application Children Elderly Others
Table of Contents Executive Summary 1 3D Printed Drugs Market Overview 1.1 Product Overview and Scope of 3D Printed Drugs 1.2 3D Printed Drugs Segment by Type 1.2.1 Global 3D Printed Drugs Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Spritam 1.2.3 Others 1.3 3D Printed Drugs Segment by Application 1.3.1 3D Printed Drugs Consumption Comparison by Application (2014-2025) 1.3.2 Children 1.3.3 Elderly 1.3.4 Others 1.4 Global 3D Printed Drugs Market by Region 1.4.1 Global 3D Printed Drugs Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global 3D Printed Drugs Market Size 1.5.1 Global 3D Printed Drugs Revenue (2014-2025) 1.5.2 Global 3D Printed Drugs Production (2014-2025) 2 Global 3D Printed Drugs Market Competition by Manufacturers 2.1 Global 3D Printed Drugs Production Market Share by Manufacturers (2014-2019) 2.2 Global 3D Printed Drugs Revenue Share by Manufacturers (2014-2019) 2.3 Global 3D Printed Drugs Average Price by Manufacturers (2014-2019) 2.4 Manufacturers 3D Printed Drugs Production Sites, Area Served, Product Types 2.5 3D Printed Drugs Market Competitive Situation and Trends 2.5.1 3D Printed Drugs Market Concentration Rate 2.5.2 3D Printed Drugs Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global 3D Printed Drugs Production Market Share by Regions 3.1 Global 3D Printed Drugs Production Market Share by Regions 3.2 Global 3D Printed Drugs Revenue Market Share by Regions (2014-2019) 3.3 Global 3D Printed Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America 3D Printed Drugs Production 3.4.1 North America 3D Printed Drugs Production Growth Rate (2014-2019) 3.4.2 North America 3D Printed Drugs Production, ... | read more...